Clinical Trials Browser

Breast Neoplasms, Neoplasm, Residual

NCT06663787 2026-05-13

HER2 CR

Active not recruiting

50 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasm, Residual

NCT07524114 2026-05-11

SHERLOCK

Recruiting

7,000 enrolled

BreastDermatologicGastrointestinalHead & NeckThoracic

Breast Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Unknown Primary, Urogenital Neoplasms, Neoplasm, Residual

NCT04434040 2026-05-04

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Phase 2 Recruiting

40 enrolled

Breast

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT07069595 2026-04-22

PREDICT-RD

Phase 2 Recruiting

78 enrolled

Breast

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT06134375 2026-04-20

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

Phase 1/2 Recruiting

204 enrolled

Breast

Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT04768426 2026-04-13

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

Phase 2 Recruiting

40 enrolled

Breast

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT04841148 2026-04-09

PALAVY

Phase 2 Recruiting

96 enrolled

Breast

Breast Neoplasms, Neoplasm, Residual

Clinical Trials

FLAMINGO-01

HER2 CR

SHERLOCK

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

PREDICT-RD

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

PALAVY